NCT04592315View on ClinicalTrials.gov

A Study to Assess the Safety, Tolerability and Pharmacokinetics of Lipovirtide in HIV-infected Patients

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

January 23, 2021

Primary Completion Date

May 2, 2023

Study Completion Date

July 11, 2023

Conditions

HIV Infections

Interventions

DRUG

Lipovirtide Injection

Single dosage of Lipovirtide Injection

Trial Locations (1)

Unknown

Beijing You'an Hospital, Beijing Medical University, Beijing

All Listed Sponsors

collaborator

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

OTHER

lead

Shanxi Kangbao Biological Product Co., Ltd.

INDUSTRY

NCT04592315 - A Study to Assess the Safety, Tolerability and Pharmacokinetics of Lipovirtide in HIV-infected Patients | Biotech Hunter | Biotech Hunter